Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial

Main Article Content

Mark Lebwohl
Jean-Philippe Lacour
Monika Liljedahl
Charles Lynde
Marie H Mørch
Diamant Thaçi
Richard B Warren

Keywords

Psoriasis, Calcipotriene, Corticosteroid, Betamethasone, Safety

Abstract

Abstract not available.

References

1. Feldman, et al. Am Health Drugs Benefits. 2016:9;504‒513

2. Armstrong, et al. JAMA Dermatol. 2013:149;1180‒1185

3. Bonnekoh, et al. EMJ Dermatol. 2017:5;36‒43

4. EMC. Enstilar Summary of Product Characteristics 2018

5. FDA. Enstilar -Prescribing Information 2019

6. Paul, et al. J EurAcadDermatolVenereol. 2017:31;119‒126; 7. Koo, et al. J DermatologTreat. 2016:27;120‒127